Nasdaq · Healthcare
HALOZYME THERAPEUTICS, INC. (HALO)
As-reported financials and recent SEC filings for HALOZYME THERAPEUTICS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.40B
Net income
$316.9M
Net margin
22.7%
Diluted EPS
$2.56
ROE
649.2%
P/E (TTM)
26.3×
Market cap
$8.89B
Debt / equity
43.9×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.40B | $1.02B | $829.3M | $660.1M | $443.3M |
| Gross profit | $1.17B | $855.9M | $636.9M | $520.8M | $361.9M |
| Operating income | $469.0M | $551.5M | $337.6M | $267.5M | $275.9M |
| Net income | $316.9M | $444.1M | $281.6M | $202.1M | $402.7M |
| Diluted EPS | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-15
View on EDGAR →32026-06-09
View on EDGAR →42026-06-03
View on EDGAR →42026-06-02
View on EDGAR →1442026-05-15
View on EDGAR →42026-05-13
View on EDGAR →1442026-05-11
View on EDGAR →10-Q2026-05-11
View on EDGAR →Go deeper on HALO
Search HALOZYME THERAPEUTICS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.